| 规格: | 98% |
| 分子量: | 398.8 |
| 包装 | 价格(元) |
| 500ug | 电议 |
| 1mg | 电议 |
Background:
Bendamustine-d4is intended for use as an internal standard for the quantification of bendamustine by GC- or LC-MS. Bendamustine is a purine analog and DNA alkylating agent.1It inhibits growth of SKW-3, Reh, CML-T1, BV-173, and HL-60 leukemia cell lines (IC50s = 27.0, 28.6, 15.6, 20.8, and 57.7 μM, respectively) but not MCF-7 and MDA-MB-231 breast cancer cell lines (IC50s = >200 μM for both).2It is cytotoxic to patient-derived lymphocytic leukemia (B-CLL) cells (LD50s = 6.8-8.3 mg/ml).3Bendamustine (50 mg/kg) inhibits tumor growth by 9 and 96% alone and in combination with ofatumumab, respectively, in a JVM-3 CLL mouse xenograft model.4It activates the DNA-damage stress response, the base excision DNA repair pathway, and apoptosis, as well as inhibits mitotic checkpoints and induces mitotic catastrophe.1Formulations containing bendamustine have been used to treat CLL and non-Hodgkin lymphoma.
1.Leoni, L.M., Bailey, B., Reifert, J., et al.Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agentsClin. Cancer Res.14(1)309-317(2008) 2.Konstantinov, S.M., Kostovski, A., Topashka-Ancheva, M., et al.Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell linesJ. Cancer Res. Clin. Oncol.128(5)271-278(2002) 3.SchwÄnen, C., Hecker, T., HÜbinger, G., et al.In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemiaLeukemia16(10)2096-2105(2002) 4.Haskova, Z., Whitacre, M.N., Dede, K.A., et al.Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemiaBr. J. Haematol.156(3)402-404(2012)
m.cnreagent.com